MedTrace Logo

A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

NCT00257478 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-06-07

No results posted yet for this study

Summary

A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.

Conditions

  • Prostate Cancer
  • Cancer of Prostate
  • Prostatic Cancer
  • Cancer of the Prostate

Interventions

DRUG

YM155

Sponsors & Collaborators

  • Astellas Pharma US, Inc.

    collaborator INDUSTRY

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • D. Buell, MD · Astellas Pharma US, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Completion
2007-03-31

Countries

  • United States
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00257478 on ClinicalTrials.gov